Genome Editing for the β-Hemoglobinopathies
The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
The β-hemoglobinopathies are diverse set of disorders caused by mutations in the β-globin (HBB) gene. Because HBB protein is a critical component (along with α-globin, heme, and iron) of hemoglobin, the molecule essential for oxygen delivery to tissues, mutations in HBB can result in lethal diseases or diseases with multi-organ dysfunction. HBB mutations can be roughly divided into two categories: those that cause a dysfunctional protein (such as sickle cell disease but also including varied diseases caused by high-affinity hemoglobins, low-affinity hemoglobins, and methemoglobinemia) and those that cause the insufficient production of HBB protein (β-thalassemia). Sickle cell disease and β-thalassemia are both the most prevalent and the most devastating of the β-hemoglobinopathies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several approaches to reducing the expression of HbF suppressors in CD34 1 cells have entered clinical trials, including the first use of CRISPR-Cas9 in humans (Figure 2).123-125”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [123]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors
Boch, J., Scholze, H., Schornack, S., Landgraf, A., Hahn, S., Kay, S., Lahaye, T., Nickstadt, A., & Bonas, U. (2009) · Science · doi:10.1126/science.1178811 · Cited by 2,470
A Simple Cipher Governs DNA Recognition by TAL Effectors
Moscou, M. J., & Bogdanove, A. J. (2009) · Science · doi:10.1126/science.1178817 · Cited by 1,988
Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain.
Kim, Y. G., Cha, J., & Chandrasegaran, S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.3.1156 · Cited by 1,889
Targeting DNA Double-Strand Breaks with TAL Effector Nucleases
Christian, M., Cermak, T., Doyle, E. L., Schmidt, C., Zhang, F., Hummel, A., Bogdanove, A. J., & Voytas, D. F. (2010) · Genetics · doi:10.1534/genetics.110.120717 · Cited by 1,869
Highly efficient endogenous human gene correction using designed zinc-finger nucleases
Urnov, F. D., Miller, J. C., Lee, Y.-L., Beausejour, C. M., Rock, J. M., Augustus, S., Jamieson, A. C., Porteus, M. H., Gregory, P. D., & Holmes, M. C. (2005) · Nature · doi:10.1038/nature03556 · Cited by 1,641
Self-citationGene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357
Cited by
DNA Damage: From Threat to Treatment
Carusillo, A., & Mussolino, C. (2020) · Cells · doi:10.3390/cells9071665 · Cited by 241
CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations
Memi, F., Ntokou, A., & Papangeli, I. (2018) · Seminars in Perinatology · doi:10.1053/j.semperi.2018.09.003 · Cited by 154
Fetal hemoglobin in sickle cell anemia
Steinberg, M. H. (2020) · Blood · doi:10.1182/blood.2020007645 · Cited by 136
Initiation of homologous recombination at DNA nicks
Maizels, N., & Davis, L. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky588 · Cited by 55
Treating sickle cell anemia: A new era dawns
Steinberg, M. H. (2020) · American Journal of Hematology · doi:10.1002/ajh.25724 · Cited by 28
“They include disrupting the erythroid enhancer of BCL11A or the binding sites for BCL11A in the γ-globin gene promoters and down-regulating the expression of BCL11A.29,30 Clinical trials are targeting BCL11A with CRISPR/Cas, zinc finger nucle- ases or shRNA (NCT03745287; NCT03653247; NCT03282656).”
Background
Metadata
- Authors
- Porteus, M. H.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Porteus, Matthew H.
- ORCID
- Porteus, Matthew H.
- Venue
- Advances in Experimental Medicine and Biology
- Publisher
- Springer New York
- Published
- 2017
- Volume
- 1013
- Pages
- 203-217
- ISSN
- 0065-2598 (ISSN-L)
- 2214-8019
- OpenAlex
- W2767217956
- Cited by
- 8
- References
- 58
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 1 · 2020: 3 · 2018: 2
- FWCI
- 4.30
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Advances in experimental medicine and biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- β-hemoglobinopathies, genome editing, beta-globin gene, sickle cell disease, beta-thalassemia, HBB mutations, methemoglobinemia, gene therapy
- MeSH terms
- Gene Editing, Anemia, Sickle Cell, Hematopoietic Stem Cells, Humans, Mutation, Transplantation, Homologous, beta-Thalassemia, Hematopoietic Stem Cell Transplantation, beta-Globins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genome Editing for the β-Hemoglobinopathies. https://app.cochat.ai/papers/10.1007/978-1-4939-7299-9_8
- The paper
- Porteus, M. H. (2017). Genome Editing for the β-Hemoglobinopathies. Advances in Experimental Medicine and Biology. https://doi.org/10.1007/978-1-4939-7299-9_8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.